Baird raised the firm’s price target on Medpace (MEDP) to $490 from $313 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace price target raised to $430 from $270 at Deutsche Bank
- TD downgrades Medpace to Sell after 55% rally
- Medpace downgraded to Sell from Hold at TD Cowen
- Medpace price target raised to $450 from $300 at Barclays
- Medpace Holdings: Hold Rating Amid Stock Surge and Uncertain Burn Rate Sustainability